secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2026-05-29T20:50:12+00:00
Accession:  0001140361-26-023336
Event type: m_and_a
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata amends merger: cash per share cut from $5 to $4, CVR increased to up to $3
--------------------------------------------------------------------------------

- Cash consideration reduced from $5.00 to $4.00 per share; CVR now offers up to $3.00 total ($1.25 + $1.75 milestone payments).
- Tender offer to commence June 1, 2026; outside date extended from July 1 to July 6, 2026.
- First CVR milestone ($1.25) tied to completion/90% enrollment of Phase 2a GBM study; second ($1.75) to NDA filing.
- Original CVR was a single $1.00 contingent payment; new structure adds potential $2.00 upside but lowers upfront cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000114036126023336/0001140361-26-023336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000114036126023336/ef20075162_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-023336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer